328 related articles for article (PubMed ID: 19008263)
21. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
22. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
Gupta A; Nath K; Bansal N; Kumar M
Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
[No Abstract] [Full Text] [Related]
23. Prognostic urinary miRNAs for the assessment of small renal masses.
Di Meo A; Brown MD; Finelli A; Jewett MAS; Diamandis EP; Yousef GM
Clin Biochem; 2020 Jan; 75():15-22. PubMed ID: 31672647
[TBL] [Abstract][Full Text] [Related]
24. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.
Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M
Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593
[TBL] [Abstract][Full Text] [Related]
25. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
[TBL] [Abstract][Full Text] [Related]
26. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.
Han WK; Alinani A; Wu CL; Michaelson D; Loda M; McGovern FJ; Thadhani R; Bonventre JV
J Am Soc Nephrol; 2005 Apr; 16(4):1126-34. PubMed ID: 15744000
[TBL] [Abstract][Full Text] [Related]
27. ARCHITECT® urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results).
Ben Khadhra H; Rose-Robert F; Herpe YE; Sevestre H; Choukroun G; Catherine L; Amant C; Saint F
Int Urol Nephrol; 2021 Jan; 53(1):59-67. PubMed ID: 32783115
[TBL] [Abstract][Full Text] [Related]
28. Detection of urinary trace elements and pattern recognition analysis in patients with renal cell carcinoma by inductively coupled plasma mass spectrometry.
Zheng J; Chen B; Liu R; Wang H; Xing J; Hang W
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1152-S1157. PubMed ID: 30539862
[TBL] [Abstract][Full Text] [Related]
29. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract][Full Text] [Related]
30. Pathway analysis of kidney cancer using proteomics and metabolic profiling.
Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH
Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452
[TBL] [Abstract][Full Text] [Related]
31. Urinary microRNAs: Looking for a New Tool in Diagnosis, Prognosis, and Monitoring of Renal Cancer.
Oto J; Plana E; Sánchez-González JV; García-Olaverri J; Fernández-Pardo Á; España F; Martínez-Sarmiento M; Vera-Donoso CD; Navarro S; Medina P
Curr Urol Rep; 2020 Mar; 21(2):11. PubMed ID: 32166474
[TBL] [Abstract][Full Text] [Related]
32. Automated Machine Learning and Explainable AI (AutoML-XAI) for Metabolomics: Improving Cancer Diagnostics.
Bifarin OO; Fernández FM
J Am Soc Mass Spectrom; 2024 Jun; 35(6):1089-1100. PubMed ID: 38690775
[TBL] [Abstract][Full Text] [Related]
33. Optical biomarker analysis for renal cell carcinoma obtained from preoperative and postoperative patients using ATR-FTIR spectroscopy.
Tian Y; Fan X; Chen K; Chen X; Peng W; Wang L; Wang F
Spectrochim Acta A Mol Biomol Spectrosc; 2024 Oct; 318():124426. PubMed ID: 38763020
[TBL] [Abstract][Full Text] [Related]
34. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility.
Rogers MA; Clarke P; Noble J; Munro NP; Paul A; Selby PJ; Banks RE
Cancer Res; 2003 Oct; 63(20):6971-83. PubMed ID: 14583499
[TBL] [Abstract][Full Text] [Related]
35. Discovery and validation of urinary biomarkers for detection of renal cell carcinoma.
Frantzi M; Metzger J; Banks RE; Husi H; Klein J; Dakna M; Mullen W; Cartledge JJ; Schanstra JP; Brand K; Kuczyk MA; Mischak H; Vlahou A; Theodorescu D; Merseburger AS
J Proteomics; 2014 Feb; 98():44-58. PubMed ID: 24374379
[TBL] [Abstract][Full Text] [Related]
36. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis.
Ganti S; Taylor SL; Abu Aboud O; Yang J; Evans C; Osier MV; Alexander DC; Kim K; Weiss RH
Cancer Res; 2012 Jul; 72(14):3471-9. PubMed ID: 22628425
[TBL] [Abstract][Full Text] [Related]
37. Proteomic evaluation of urine from renal cell carcinoma using SELDI-TOF-MS and tree analysis pattern.
Wu DL; Zhang WH; Wang WJ; Jing SB; Xu YM
Technol Cancer Res Treat; 2008 Jun; 7(3):155-60. PubMed ID: 18473487
[TBL] [Abstract][Full Text] [Related]
38. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
[TBL] [Abstract][Full Text] [Related]
39. 14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid.
Minamida S; Iwamura M; Kodera Y; Kawashima Y; Tabata K; Matsumoto K; Fujita T; Satoh T; Maeda T; Baba S
Anal Bioanal Chem; 2011 Jul; 401(1):245-52. PubMed ID: 21553213
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
